Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease

NCT03749447 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03749447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney Disease
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
March 8, 2019
Completion date
August 23, 2023
Enrollment
270 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, autosomal dominant polycystic kidney, chronic kidney diseases